{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:39:23Z","timestamp":1779151163974,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:00Z","timestamp":1146096000000},"content-version":"vor","delay-in-days":3861,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[1995,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\n\t\t\t\t\t<\/jats:bold> Sedation limits the clinical utility of classical H, antihistamines. while newer antihistamincs such as loratadine and terfenadine arc non\u2010sedating. However, clinical use of terfenadine has been associated with rare but severe cardiac arrhythmias, in particular lorsades de pointes.<\/jats:p><jats:p><jats:bold>Objective\n\t\t\t\t\t<\/jats:bold> To establish a quantitative experimental model for assessing the sedating and cardiotoxicity potential of non\u2010sedating and sedating antihistamines.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold> Drugs were administered intravenously and the integrated amplitude of the conical electroencephalogram (EEC) signal was recorded. The threshold dose that depressed EEG activity was compared with the dose required lo inhibit by 50% the peripheral bronchospasm elicited by 10 \u03bcg\/ kg i.v., of histamine. In separate studies, the electrocardiogram (ECG) and cardiovascular effects of loratadine (30 and 100mg\/kg, i.v.). terfeuadine (10mg\/kg. i.v.). promethazine (5mg\/kg. i.v.) and diphenhydramine (20 mg kg, i.v.) were evaluated.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> The sedating antihistamines. diphenhydramine and promethazine. depressed the integrated EEG at doses between 0.6 and 2.0 limes their peripheral antihisiamine doses. Loratadine had no EEG depressant activity at 100 mg kg. i.v., a dose more than I 70 times its LD50 (0.58 mg kg, i.v.) against histamine bronchospasm. We were unable lo evaluate the EEG effects of terfenadine. because it produced cardiovascular collapse at 10 mg\/kg. i.v. Loratadine and promethazinc did not produce adverse cardiovascular effects. nor did they alter normal ECG activity. Diphenhydramine produced brady\u2010cardia followed by a transient hypertensive phase without affecting the QTc interval. In contrast, terfenadine elicited hypotension, bradycardia and significant arrhythmogenic activiy, causing a prolongation of the QTc interval and a torsades de pointes like ventricular arrhythmia. Pharmacokinetic studies after i.v. administration of loraladine (30 and 100 mg\/kg) demonstrated plasma levels of loratadine and its major metabolite descarboethoxyloratadine to be several orders of magnitude greater than levels found in humans at the clinical dose of 10mg.<\/jats:p><jats:p><jats:bold>Conclusion\n\t\t\t\t\t<\/jats:bold> The CNS depressant effects of H<jats:sub>1<\/jats:sub> antihislamines arc promcthazine\u2245 diphenhdramine \u226b loratadine = placebo. Of the non\u2010sedating antihistamines. loratadine was devoid of adverse cardiovascular effects whereas terfenadine caused a pronounced disruption of the normal ECG. characterized by a torsades de pointes\u2010like effect.<\/jats:p>","DOI":"10.1111\/j.1365-2222.1995.tb00400.x","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T14:52:32Z","timestamp":1146235952000},"page":"974-984","source":"Crossref","is-referenced-by-count":23,"title":["Antihistamine activity, central nervous system and cardiovascular profiles of histamine H<sub>1<\/sub> antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea\u2010pigs"],"prefix":"10.1111","volume":"25","author":[{"given":"J. A.","family":"HEY","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"DEL PRADO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. M.","family":"CUSS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. W.","family":"EGAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"SHERWOOD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.\u2010C.","family":"LIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"KREUTNER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"509","article-title":"Evaluation of the CNS Properties of Sch 29851. a Potential Non\u2010Sedating Antihistamine","volume":"14","author":"Barnell A.","year":"1984","journal-title":"Agents Actions"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(87)80197-5"},{"key":"e_1_2_1_4_2","first-page":"350","article-title":"H\u20101 Reeeptor Antagonists: Comparative Tolerabitity and Safely","volume":"10","author":"Simons KER.","year":"1994","journal-title":"Drug Exp"},{"key":"e_1_2_1_5_2","first-page":"34","article-title":"Terfenadine","volume":"29","author":"Sorkin EM","year":"1985","journal-title":"A Review of its Pharmacodynamic Properties and Therapeutic Etficacy Drugs"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6790.1469-b"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450210088038"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80252-5"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.135"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259230"},{"key":"e_1_2_1_11_2","first-page":"1471","article-title":"Torsades de Poinles Associated with Drugs and Toxins: Recognition and Management","volume":"113","author":"Straimann HG.","year":"1987","journal-title":"Am Heart J"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.1993.03500120070028","article-title":"Mechanism of the Citrdiotoxic Actions of Terfenadine","volume":"269","author":"Woolsey RL","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_1_13_2","first-page":"353","article-title":"An Analysis of the Time\u2010Relations of Electrocardiograms","volume":"7","author":"Bazet HC.","year":"1920","journal-title":"Heart"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(76)90471-9"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.64.6.1167"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(94)80078-2"},{"key":"e_1_2_1_17_2","first-page":"346","volume-title":"Statistical Theory and Methodology in Science and Engineering","author":"Brownlee KA.","year":"1965"},{"key":"e_1_2_1_18_2","first-page":"635","volume-title":"The Pharmacological Basis of Therapeutics","author":"Douglas WW.","year":"1970"},{"key":"e_1_2_1_19_2","first-page":"42","article-title":"Comparative Study of EEG Effects of Antihistamines in Normal Volunteers","volume":"8","author":"Goldstein L","year":"1986","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00544062"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","unstructured":"LeviR.OwenDAA.Trezciakowski J. Actions of Histamine on the Heart and Vasculalure. In:Pharmacology of Histamine Receptors. Wright PSG1982: p236.","DOI":"10.1016\/B978-0-7236-0589-8.50012-0"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00129a026"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01964951"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1993.tb00215.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90199-8"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90037-D"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1987.tb03090.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198937010-00003"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.1995.tb00400.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.1995.tb00400.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T08:19:49Z","timestamp":1698308389000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.1995.tb00400.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1995,10]]}},"alternative-id":["10.1111\/j.1365-2222.1995.tb00400.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.1995.tb00400.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,10]]}}}